These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30104997)

  • 21. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies.
    Boyd JT; Zadikoff C; Benesh JA; Zamudio J; Robieson WZ; Kukreja P; Yokoyama M; Siddiqui MS
    Clin Park Relat Disord; 2020; 2():25-34. PubMed ID: 34316616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.
    Virhammar J; Nyholm D
    Ther Adv Neurol Disord; 2017 Mar; 10(3):171-187. PubMed ID: 28344656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson's disease.
    Shackleford MR; Mishra V; Mari Z
    Clin Park Relat Disord; 2022; 7():100148. PubMed ID: 35756075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.
    Standaert DG; Rodriguez RL; Slevin JT; Lobatz M; Eaton S; Chatamra K; Facheris MF; Hall C; Sail K; Jalundhwala YJ; Benesh J
    Mov Disord Clin Pract; 2017; 4(6):829-837. PubMed ID: 29242809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
    Chaudhuri KR; Antonini A; Pahwa R; Odin P; Titova N; Thakkar S; Snedecor SJ; Hegde S; Alobaidi A; Parra JC; Zadikoff C; Bergmann L; Standaert DG
    J Parkinsons Dis; 2022; 12(7):2071-2083. PubMed ID: 35964203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.
    Kamel WA; Al-Hashel JY
    Brain Behav; 2020 Sep; 10(9):e01757. PubMed ID: 32677345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.
    Lew MF; Slevin JT; Krüger R; Martínez Castrillo JC; Chatamra K; Dubow JS; Robieson WZ; Benesh JA; Fung VS
    Parkinsonism Relat Disord; 2015 Jul; 21(7):742-8. PubMed ID: 25962554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.
    Murata M; Mihara M; Hasegawa K; Jeon B; Tsai CH; Nishikawa N; Oeda T; Yokoyama M; Robieson WZ; Chatamra K; Facheris MF; Benesh J
    Ther Adv Neurol Disord; 2018; 11():1756286418759315. PubMed ID: 29511383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
    Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa-Carbidopa Intestinal Gel for Parkinson's Disease over 11 years: One Center's "Real-World" Experience.
    Vekhande C; Hamed M; Tremain G; Mah J; Shetty A; Lazarescu A; Suchowersky O
    Can J Neurol Sci; 2023 Jul; ():1-8. PubMed ID: 37462070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
    Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.